NextEra Falls, Seagate Slips, Regeneron Tumbles - podcast episode cover

NextEra Falls, Seagate Slips, Regeneron Tumbles

May 18, 20264 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that’s struggling to meet the surge in electricity consumption. Dominion shares rose 9.4% to $67.56 as trading closed in New York on Monday, while NextEra fell 4.6% to $89.04.


-Seagate (STX) shares fell 6.9% Monday in its worst one-day drop in nearly two months after management comments at a JPMorgan conference sparked investor fears that the company won’t be able to keep up with soaring demand for memory chips. The declines come after a blistering rally in the sector that’s spanned roughly eight weeks, boosted by solid earnings from megacap technology hyperscalers, a slew of deals for the cohort and investor enthusiasm in the risk-on trade as high demand for artificial intelligence infrastructure persists. The SOX gained nearly 60% from the start of April through a May 11 record high.

- Regeneron Pharmaceuticals (REGN) said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues. The shares plunged in trading on Monday.

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

Bloomberg Audio Studios, podcasts, radio News.

Speaker 2

The Stock Movers report, your roundup of companies making moves in the stock market, harnessing the power of Bloomberg Data.

Speaker 3

And Jim Cenebec along with Carol Masser, We're joined by Alexandra Semenova. She is Bloberg News Equities reporter and she is at Bloomberg headquarters in New York. Alex what are you watching, hey, guys?

Speaker 1

So this was the deal of the day today. All attention from investors was on this mega deal. Next Era Energy agreed to buy Dominion Energy for about sixty seven million billion dollars rather in stock. This is the biggest power acquisition ever. This merger creates a giant utility company that extends from Florida to all the data centers in Virginia and really highlights the demand for electricity when it

comes to the buildout of artificial intelligence. And just looking at the share moves today, next Era down about four point six percent on but Dominion Energy closing up nine point four percent. Next Era would pay the equivalent of about seventy six dollars per share for Dominion. The company said this in a statement today, confirming Bloomberg reporting that represents a takeover premium of about twenty three percent based on Friday's closing price.

Speaker 3

Guys, not too savvy and always good to be the target rather than the acquirer. You see the play out, Hey, talk to us about Seagate Technology.

Speaker 2

We know you've been watching this one today.

Speaker 1

Yeah, this one was really highlighting how fragile the AI trade is getting after six consecutive weeks of gains. Any disappointing results for the chip makers could really see this unwind continue like it has been over the last couple of trading days. Seagate Technology sliding today ten percent, having its worst day since last April at the onset of tariffs. This is after management commentary at a JP Morgan conference saying that they basically don't expect that they'll be able

to meet the demand for memory chips. Ce CEO said that building new factories would quote take too long. That comment really spooking investors, and the declines, of course come amid a torrid rally in semiconductors broadly. We also saw other companies falling today in sympathy, SanDisk, Credo Technology, and of course the Philadelphia Stock Exchange. Semiconductor index also down on the day.

Speaker 3

All right, So from chips and memory to pharmaceutic goals regeneron, what's going on with degeneron today.

Speaker 1

Yeah, a really disappointing result for this company on a Phase three trial for its melanoma drug. This led to at least ten analysts across Wall Street slashing their rating on the stock and seeing shares decline in a big way. Looking at the company, it is down nine point eight percent, which is the worst day since May thirtieth of last year.

The biotech was aiming to show some improvement in patients with metastatic melanoma, but they didn't have a statistically significant enough number when it came to how long patients lived before their cancer progressed. BEMO analyst said that this was a huge inflection point for the first half of twenty twenty six. They were expecting positive results, and they said that sentiment was inextricably tied to how this trial would go, hence disappointing investors.

Speaker 2

The stock Moover's report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street and for the latest market moving headlines. Listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business app.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android